Cell Logistics began as a discovery in the UW-Madison Department of Medicine and sprouted into a company with the mission to commercialize a product to aid in the treatment of heart disease. Eric Schmuck, Ph.D.; Amish Raval, M.D.; and Peiman Hematti, M.D. cofounded Cell Logistics, Inc. in 2016. Alex Vodenlich, M.S. joined the team in 2018 as President and CEO.
The company’s focus is to deliver a product that will minimize the damage following a heart attack and help preserve heart function. The product aims to lower the occurrence of heart failure.
The company’s product, a biomaterial called iCFX, is an innovation shown to minimize tissue damage and assist in restoring blood flow after a heart attack. It is produced from adult stem cells, which sets it apart from the competition. Other companies have produced animal-derived and synthetic biomaterials, but these have not yet shown strong effectiveness.
Cell Logistics has secured an exclusive license for key intellectual property through the Wisconsin Alumni Research Foundation (WARF). This arrangement grants Cell Logistics the rights to use and commercialize iCFX.
Read the full article here: https://wisconsinctc.org/client-successes/cell-logistics/